Aristen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aristen

What is Aristen? (Clotrimazole)

Property Description
Active Ingredient Clotrimazole
Pharmacological Class Antifungal (Azole/Imidazole)
Origin Synthetic compound
Primary Forms Sterile eye ointment, topical cream, vaginal tablets
General Purpose To eliminate or inhibit fungal and yeast organisms

Aristen: What Type of Medication is Clotrimazole?

Aristen is a synthetic, broad-spectrum antifungal medication whose active ingredient is Clotrimazole (C22H17ClN2), designed to eliminate or inhibit pathogenic fungi and yeasts. It is classified as an imidazole derivative and belongs to the larger azole class of antimycotics, a group of compounds defined by their specific mechanism of action against fungal structures. Pharmacological studies have consistently supported the efficacy of this class against a wide array of fungal organisms. This drug is a synthetically produced compound, not derived from natural sources, that gained clinical recognition for its targeted activity against mycotic outbreaks.

Composition and Available Forms of Aristen

The drug Aristen is typically manufactured as a single-entity active product, containing only Clotrimazole as its primary therapeutic substance, combined with varied inert bases for localized application. A key differentiator for the active substance is its specialized preparation in forms like the sterile eye ointment for ophthalmic use, a form requiring stringent manufacturing standards, as well as topical cream, topical solution, oral lozenges, and vaginal tablets. These varied forms ensure the active agent is delivered locally through the ophthalmic, cutaneous, oral, or vaginal route of administration.

General Purpose: The Function of an Imidazole Antifungal

The fundamental purpose of Aristen is to function as a fungicidal agent, directly causing the death of fungal organisms. Its core mechanism involves altering the permeability barrier of the fungal cell membrane by inhibiting the biosynthesis of ergosterol, a sterol essential for the fungal cell's structural integrity. This widely recognized mechanism provides its general utility as an effective antimycotic drug for conditions involving yeast and dermatophyte overgrowth.

Regulatory References

  1. NIH/StatPearls - Clotrimazole Pharmacology

What side effects are possible with Aristen?

Possible Side Effects and Safety Information

The safety profile of Aristen (Clotrimazole) is primarily defined by its minimal systemic absorption following topical or vaginal application, which tends to limit adverse reactions to the site of administration. Adverse events are officially classified into System-Organ-Classes (SOCs) such as Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions in regulatory documents.


Officially Documented Adverse Reactions

The most commonly observed adverse reactions are localized symptoms at the application site. These include a burning or stinging sensation, itching (pruritus), redness (erythema), pain, discomfort, and irritation. The frequency of many effects is often classified as Frequency Not Known due to reliance on voluntary post-marketing reports, which limits precise incidence assignment.

Serious adverse reactions are rare but documented under Immune System Disorders and include signs of systemic hypersensitivity. These reactions encompass severe events like anaphylactic reaction, angioedema (swelling), hypotension, and dyspnea (difficulty breathing).


Safety Considerations and Restrictions

Official regulatory documents note specific safety constraints. Aristen is contraindicated in individuals with a known history of hypersensitivity to Clotrimazole or any of its excipients. The topical cream or solution is not for ophthalmic use and should avoid contact with the eyes.

For vaginal formulations, a temporary safety note exists: the medication may reduce the effectiveness and safety of latex contraceptive products (condoms and diaphragms) during the treatment period.

Regarding special populations, use during the first trimester of pregnancy is often avoided as a precautionary measure, though minimal systemic absorption is not expected to pose a hazard during breastfeeding. The label for systemically absorbed forms, like oral troches, advises periodic assessment of hepatic function in patients with pre-existing hepatic impairment.

Overdose and Emergency Response

The official regulatory profile for Aristen (Clotrimazole) addresses overdose primarily in the context of accidental oral exposure, reflecting its local route of application. Acute overdosage with topical or vaginal use is officially classified as unlikely to lead to acute intoxication or a life-threatening situation due to minimal systemic absorption.

The critical concern outlined in official documents is accidental oral ingestion. In such events, documented manifestations that may become apparent include Dizziness, Nausea, and Vomiting.

Domain Official Regulatory Statements
Exposure Factor Acute overdosage with topical use is classified as unlikely to cause significant systemic harm.
Immediate Action Following accidental oral ingestion, Seek professional assistance and Contact a Poison Control Center immediately.

When immediate medical help is required, the official guidance emphasizes intervention following the accidental swallowing of the medication, particularly if the documented symptoms are present. Management for overdose is restricted to Symptomatic and supportive treatment, as regulatory information confirms that no specific antidote is known. Procedural steps like gastric lavage are rarely required and considered only if pronounced clinical symptoms become apparent after accidental ingestion. Regulatory documents do not define population-specific overdose risks or monitoring requirements.

Therapeutic Uses of Aristen

What Aristen Treats: Main Uses and Benefits

Aristen (Clotrimazole) is generally used in situations involving certain distressing symptoms linked to localized fungal and yeast infections. Its therapeutic relevance is focused on conditions where symptoms that interfere with daily functioning create noticeable physiological strain.

This class of medicine is used to treat a variety of fungal and yeast infections, serving a role in supportive symptom management.

Therapeutic Focus Areas

The medication is commonly used across conditions presenting with acute or episodic manifestations, including common infections like Athlete's Foot, Ringworm, Jock Itch, Vaginal Thrush, and Oral Thrush. Aristen helps address symptom clusters that may become intense or disruptive, such as pronounced itching, burning, and visible signs of skin irritation.

It is generally relevant when supportive symptom management is appropriate for conditions involving recurrent or unstable symptom patterns, supporting the patient during episodes of heightened discomfort. It assists with managing symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.


Quick Fact: Supportive Management for Irritative States

Aristen is commonly used to help with the symptoms related to inflammatory or irritative states caused by mycotic overgrowth, providing support that may help ease the overall symptom load during periods of heightened physical discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility profile for Aristen (Clotrimazole) is defined by official regulatory labeling across absolute contraindications, age limits, and conditional use requirements. The primary absolute restriction is a contraindication for individuals with a known hypersensitivity to clotrimazole or any component of the specific formulation. This may include specific excipients like soya oil present in certain vaginal products.

Eligibility is dependent on age and the medicine’s form. The oral lozenge form is not recommended for children under the age of three years, as safety has not been established in this group. Additionally, some vaginal formulations are restricted from use in adolescents under 16 years and older adults over 60 years.

Use is conditional during specific life stages. Regulatory agencies state that use during the first trimester of pregnancy is restricted to cases where it is clearly indicated due to insufficient data from controlled studies. Caution is advised for nursing mothers, as it is unknown if the drug is excreted in human milk. For the oral lozenge form, patients with preexisting hepatic impairment require periodic assessment of liver function. Furthermore, topical formulations are explicitly not for ophthalmic use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Aristen (Clotrimazole) is primarily defined by the minimal systemic absorption of its topical and vaginal formulations, though two distinct interaction domains are officially documented.

Systemic Metabolic Interaction

Product Category Specific Interacting Medicines
Immunosuppressive agents Tacrolimus, Sirolimus

For oral formulations, the active ingredient is identified as a moderate inhibitor of the Cytochrome P450 (CYP) 3A4 enzyme. This pharmacokinetic interaction may increase the plasma concentration of co-administered medicines that are substrates of this enzyme, such as the immunosuppressants Tacrolimus and Sirolimus. Regulatory documents note that the blood levels of these specific medicines may be elevated, requiring monitoring, particularly in populations like transplant patients.

Local Physicochemical Interaction

The use of vaginal formulations of Aristen is subject to an interaction-related constraint concerning latex contraceptive devices (e.g., condoms and diaphragms). The product may cause damage to the latex material, potentially reducing the device's protective function. Therefore, official labeling advises the use of alternative precautions for at least five days following treatment with the vaginal product. No formal interactions with food, alcohol, or herbal products are documented in regulatory prescribing information for topical or vaginal use.

Mechanism of Action

Aristen acts as an inhibitor targeting the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme is critical for the conversion of lanosterol to ergosterol, an essential sterol component of the fungal cell membrane. The molecular interaction disrupts ergosterol biosynthesis, leading to a profound depletion of ergosterol in the membrane structure.

This intracellular deficit of ergosterol results in altered membrane fluidity and increased permeability. The loss of membrane integrity culminates in the leakage of vital cellular constituents from the fungal cell and a subsequent inhibition of fungal cell replication and growth. The system-level physiological consequence is the localized modulation of fungal load within the targeted tissue.

Dosage and Administration Information

How to Use Aristen (Clotrimazole)

Aristen (Clotrimazole) administration is strictly localized, utilizing specific formulations designed for direct application to the affected area. The administration protocol involves precise rules for route, dosage, frequency, and duration.


Official Administration Guidelines

Usage Domain Description of Labeled Instruction
Administration Routes Primarily Topical (Cutaneous), Intravaginal, Oral (Local/Transmucosal), and Otic routes, depending on the specific dosage form.
Standard Frequencies Dermal creams and otic solutions are typically applied twice daily. The oral lozenge is used five times a day, and vaginal forms are usually administered once daily.
Dosage Forms & Strengths Available in 1% topical creams, 10 mg oral lozenges, and vaginal tablets ranging from 100 mg to 500 mg for varying course lengths.
Duration Requirement Treatment duration ranges from single-day regimens (500 mg vaginal tablet) to 14 consecutive days (oral lozenge), or up to 4 weeks for some topical uses. Topical application may continue for one week after clinical clearance.

Administration Specifics

Proper use is defined by technique and timing. The oral lozenge must be slowly dissolved in the mouth and must not be chewed or swallowed whole. Vaginal administration is generally directed to occur at bedtime to optimize retention. For the topical form, the medicine should be massaged gently into the affected area and the surrounding healthy skin. Standard guidelines advise against using occlusive (air-tight) dressings over the application site unless specifically instructed. These specific constraints structure the protocol to ensure localized delivery and adherence to the fixed, non-systemic use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Initial Research Focus

Research has explored the drug's characteristics, including its engagement with the A2 receptors, which are implicated in C syndrome pathology. Studies examined the drug's absorption, distribution, metabolism, and excretion (ADME) profile.

Early-stage research involved in-vitro studies and small, non-randomized human trials. Some studies reported findings that supported further investigation in controlled settings.


Key Investigation and Outcome Studies

Several randomized controlled trials (RCTs) have investigated the study endpoints related to chronic C syndrome. These studies focused on specific measures, including changes in the S1 Symptom Score and the QOL (Quality of Life) index.

  • Phase 2 Trials: Early dose-finding studies investigated whether various dosages were associated with changes in the S1 Symptom Score over 8 weeks. Findings from these trials were mixed regarding the optimal therapeutic range.
  • Phase 3 Trials: In a large Phase 3 trial, researchers reported an observation regarding symptom scores over 12 months. This trial compared the drug against a placebo group, focusing on the percentage of participants reporting a 50% decrease in S1 score. Comparative research was conducted against placebo and other treatments.

Studies on Combination Investigation

Studies have explored whether the combination of the drug with a standard D1 therapy was investigated against study endpoints, specifically in patients with treatment-resistant C syndrome.

  • One meta-analysis of three Phase 3 trials evaluated whether the combination was associated with a statistically significant difference in achieving remission compared to D1 therapy alone. Findings provided data points that remain limited.

Safety and Tolerability Data

Research gathered data on the profile of adverse events associated with long-term use. Across clinical trials, headache, nausea, and fatigue were the most frequently documented adverse events. Severity was reported as mild to moderate.

  • Drug-Drug Interactions: Research has investigated how the drug interacts with commonly co-administered medications, such as M1 and M2.
  • Discontinuation: Studies did not evaluate clinical recommendations for discontinuation. Trials evaluated the data related to participant withdrawal.

Frequently Asked Questions (FAQ)

Common questions about Aristen (FAQ)


Q: What is the main thing Aristen is used for?

Regulatory documents indicate that Aristen (Clotrimazole) is approved to treat various fungal infections in the body. This includes conditions such as oral candidiasis (commonly known as thrush), as well as common infections like athlete's foot, ringworm, jock itch, and vulvovaginal candidiasis (yeast infections).


Q: Is Aristen a new type of drug?

The active ingredient in Aristen, Clotrimazole, has been in clinical use for a long time. However, official information shows that new forms of the medicine, such as the otic (ear) solution, have received FDA approval more recently.


Q: How quickly does Aristen typically start to work?

Official information from regulatory sources suggests that patients often begin to experience relief and clinical improvement within the first week of starting treatment. This usually involves a reduction in symptoms like itching or burning, depending on the site of application.


Q: How long do the effects of Aristen last in the body?

Aristen is designed for local treatment and is not administered to circulate widely throughout the body. Official summaries indicate that for the vaginal form, fungicidal concentrations (the amount needed to inhibit fungi) remain present in the local area for up to 3 days after application.


Q: Can Aristen cause me to feel tired or dizzy?

Official product information, often related to systemic exposure or allergic reactions, mentions potential side effects like dizziness and drowsiness. Additionally, the drug's safety profile has included fatigue as one of the most frequently reported adverse events in clinical trials.


Q: Is it normal to have mild stomach upset when first starting Aristen?

Some official labeling notes that the medication may cause general adverse effects such as nausea and vomiting. Furthermore, some formulations used vaginally may be associated with symptoms like lower stomach pain or pelvic discomfort.


Q: Can I take Aristen if I am already taking supplements?

Official regulatory information emphasizes the importance of reviewing all vitamins, nutritional supplements, and herbal products with a healthcare provider. This is because information regarding potential safety issues when combining Aristen with many non-prescription supplements may be limited.


Q: Does Aristen interact with common over-the-counter pain relievers?

Specific interaction checkers from regulatory-affiliated sources have reported no formal interactions between Clotrimazole and the common OTC pain reliever Paracetamol (Acetaminophen). For all medicines, official safety practices suggest reviewing their use with a healthcare provider.


Q: Is Aristen safe for older adults or seniors?

For several forms of Aristen, including intravaginal and oral use, the recommended dosages for adults and geriatric patients are the same. Official regulatory warnings noted that some vaginal formulations are restricted from use in older adults over the age of 60.


Q: What happens if I miss a dose of Aristen?

The official product labeling for the oral lozenge contains specific instructions for missed doses. These instructions outline procedures for how to manage a missed dose when remembered, and when to instead skip the missed dose and resume the normal administration schedule. Following these label instructions is necessary.


Q: Is there a generic version of Aristen available?

The active ingredient in Aristen is Clotrimazole, which is a widely available substance. Official records confirm that Clotrimazole is sold under many generic and different brand names and is not exclusively marketed under the brand name Aristen.


Q: Can Aristen impact my ability to drive or operate machinery?

Official documents list potential side effects such as dizziness and drowsiness. Due to these potential central nervous system effects, caution is generally recommended regarding the operation of complex machinery or driving if these symptoms are experienced.


Q: Why do doctors prescribe Aristen for this specific condition?

Doctors prescribe Aristen because its active ingredient is a synthetic imidazole with broad-spectrum antimycotic activity to eliminate or inhibit the growth of pathogenic fungi and yeasts. The drug is prescribed according to its specific FDA-approved and labeled indications.


Q: Is Aristen approved in countries outside of the United States?

Official regulatory documents from various governmental bodies such as the European Medicines Agency (EMA) and Health Canada frequently reference the drug and its active ingredient (Clotrimazole). This suggests that Aristen and its generic forms are approved and in use in many countries outside of the United States.


Q: Are there any specific safety warnings related to Aristen and heart health?

Official labeling for the oral lozenge warns that because the drug affects the CYP3A4 enzyme, it may interact with certain heart medicines. Specifically, when combined with some calcium channel blockers, there is a potential risk of complications like worsening congestive heart failure, requiring monitoring.


Q: Does Aristen make other medicines less effective?

Official regulatory warnings indicate that vaginal formulations of Clotrimazole can cause damage to latex contraceptive devices (such as condoms and diaphragms). This damage can cause the device to fail, thereby making it less effective at providing protection.


Q: How soon after starting Aristen might I expect to see the full benefit?

According to official product information, the time to achieve the full benefit depends on the condition being treated. Symptoms for common infections like ringworm or jock itch typically resolve within 2 to 4 weeks of treatment. Conditions such as athlete's foot may require a full treatment course of at least 4 weeks.


Q: What are the common reasons why Aristen might be discontinued?

Official product labeling describes that discontinuation of treatment is indicated if signs of local irritation or sensitivity develop at the application site. Such signs include burning, itching, redness, or blistering that is not tolerable.


Q: Is Aristen a prescription-only medicine?

The regulatory status of Aristen depends on its formulation and strength. The active ingredient, Clotrimazole, is available in the market as both a prescription drug (e.g., the oral lozenge form) and as an over-the-counter (OTC) medicine (e.g., many topical creams and certain vaginal products).


Q: Does Aristen help with energy levels?

No regulatory documentation mentions the drug having a positive effect on energy levels. The drug's safety profile has listed fatigue as one of the most frequently reported adverse events in clinical trials.


Q: Is Aristen ever used for conditions other than the main one listed?

Official regulatory documents note that in addition to the common fungal infections, Clotrimazole is also included in certain combination products to treat other infections. These sometimes include conditions such as otitis externa (ear infection) and mixed bacterial/fungal skin infections.


Q: Can I take Aristen with my blood pressure medicine?

Caution is advised, as official interaction checks show that the oral lozenge form of Aristen can interact with certain blood pressure medicines known as calcium channel blockers (CCBs). This interaction is officially noted as a potential drug-drug interaction.

How should Aristen be stored and disposed of?

How to Store and Dispose of Aristen?

The storage and disposal of Aristen (Clotrimazole) must strictly follow official regulatory requirements to ensure product integrity and safety.


Official Storage Requirements

Condition Regulatory Mandate
Temperature Store at room temperature, typically between 2 C and 30 C.
Handling Keep from freezing and away from excess heat and moisture.
Container Must be kept in the tightly closed container it came in.
Child Safety Store medication out of the sight and reach of children.

Official Disposal Rules

Expired or unneeded Aristen should be discarded according to local regulations. It is officially mandated not to flush this medication down the toilet or dispose of it in drains to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aristen found in:

A-Z Index: